Catalyst biosciences, inc. (CBIO)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
License and collaboration revenue

16,366

-

-

-

-

0

0

0

6

-

318

111

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contract revenue

-

-

-

-

-

-

-

-

-

-

-

-

271

72

109

109

109

110

109

859

672

-

547

297

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

License fees and milestones from collaborations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Grant and other revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

87

-

-

-

-

-

-

-

-

-

-

-

-

-

-

License fees and milestones from collaborations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

3,536

590

736

33,487

22,607

18,820

18,538

20,699

38,922

21,662

20,704

Grant and other revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

32

158

250

125

417

44

72

136

198

Net operating revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

87

-

0

0

3,536

590

768

33,645

22,857

18,945

18,955

20,743

38,994

21,798

20,902

Operating expenses:
Reduction in force (including stock-based compensation of $278 and $698 for the three and six months ended June 30, 2015, respectively)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,312

-

-

0

-

-

-

-

Total operating expenses

21,434

13,987

13,195

14,381

15,714

11,684

8,345

7,114

6,685

6,147

6,196

6,055

4,442

5,291

5,821

5,024

4,681

4,794

3,994

3,060

3,704

-7,213

2,185

2,507

11,843

-26,801

13,146

12,488

11,810

16,850

8,866

19,411

20,871

29,090

28,286

23,314

26,692

19,381

15,936

Research and development

13,264

10,794

9,927

11,111

12,027

8,239

5,575

3,889

3,771

3,580

3,805

3,401

2,061

3,121

3,396

2,752

2,286

1,767

1,486

1,322

1,383

-6,436

1,336

1,287

9,080

-21,529

10,312

9,454

8,320

12,340

6,434

12,512

17,801

26,069

25,444

20,185

23,517

17,329

14,122

General and administrative

3,691

3,193

3,268

3,270

3,687

3,445

2,770

3,225

2,914

2,567

2,391

2,654

2,381

2,170

2,425

2,272

2,395

3,027

2,508

1,738

2,321

-777

849

1,220

2,763

-5,272

2,834

3,034

3,490

3,104

2,432

4,587

3,070

3,021

2,842

3,129

3,175

2,052

1,814

Loss from operations

-5,068

-13,987

-13,195

-14,381

-15,714

-11,684

-8,345

-7,114

-6,679

-5,829

-5,878

-5,944

-4,171

-5,219

-5,712

-4,915

-4,572

-4,684

-3,885

-2,201

-3,032

8,095

-1,638

-2,210

-11,756

23,788

-13,146

-12,488

-8,274

-16,260

-8,098

14,234

1,986

-10,145

-9,331

-2,571

12,302

2,417

4,966

Interest and other income, net

1,015

378

489

601

631

847

651

632

1,637

76

85

67

33

1,470

941

82

980

-445

273

516

174

-

136

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

178

-

257

131

224

-

239

280

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

299

-

316

343

316

360

366

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,439

39

-

-

-

-

9

-

13

14

16

18

20

22

26

33

39

29

31

34

38

Other Income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

135

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total other income (expense)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

169

-

244

117

208

289

219

258

273

340

277

314

285

326

328

Loss before taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-11,587

-

-12,902

-12,371

-8,066

-

-

-

-

-

-

-

-

2,743

5,294

Income tax expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,412

-

-

-

-

-

-

-

-

-

-

-

-

257

1,512

Net loss

-4,053

-13,609

-12,706

-13,780

-15,083

-10,837

-7,694

-6,482

-5,042

-5,753

-5,793

-5,877

-4,138

-3,749

-4,771

-4,833

-3,592

-5,129

-5,051

-1,724

-2,858

11,963

-1,502

-2,075

-14,999

23,373

-12,902

-12,371

-8,066

-15,870

-7,879

14,492

2,259

-9,805

-9,054

-2,257

12,587

2,486

3,782

Deemed dividend for convertible preferred stock beneficial conversion feature

-

-

-

-

-

-

-

-

-

-

-

3,951

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-5,793

-9,828

-

-

-4,771

-4,833

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per share attributable to common stockholders, basic and diluted

-0.28

-1.13

-1.06

-1.15

-1.26

-0.94

-0.64

-0.54

-0.56

0.99

-1.34

-2.53

-4.57

-4.67

-6.04

-6.33

-4.71

-36.79

-0.93

-4.60

-7.67

-13.25

-4.08

-0.22

-0.44

-26.30

-0.38

-0.37

-0.24

-

-

-

-

-

-

-

-

-

-

Shares used to compute net loss per share attributable to common stockholders, basic and diluted

14,592

12,041

12,022

11,989

11,963

11,984

11,942

11,938

8,989

4,601

4,310

3,877

906

801

789

763

762

-4,977

5,410

374

372

-42,217

368

9,572

33,746

-99,426

33,644

33,626

33,616

-

-

-

-

-

-

-

-

-

-

Basic net (loss) income per share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.24

0.43

0.07

-

-0.27

-0.07

0.43

0.09

0.13

Diluted net (loss) income per share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.24

0.43

0.07

-

-0.27

-0.07

0.41

0.08

0.13

Weighted average common shares outstanding - basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

33,494

33,409

33,390

-

33,377

30,725

28,996

28,622

28,509

Weighted average common shares outstanding - diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

33,494

33,638

33,822

-

33,377

30,725

30,399

30,173

30,152

Net loss

-4,053

-13,609

-12,706

-13,780

-15,083

-10,837

-7,694

-6,482

-5,042

-5,753

-5,793

-5,877

-4,138

-

-4,771

-4,833

-

-

-

-

-

-

-1,501

11,189

-14,999

-

-12,902

-12,371

-8,066

-15,870

-7,879

14,492

2,259

-9,805

-9,054

-2,257

12,587

2,486

3,782

Unrealized (loss) gain on available-for-sale securities, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-21

-

109

-202

-13

-176

183

-33

191

-

-218

-5

-

-

-

Unrealized gain on available-for-sale securities, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

204

-

-

Comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-15,020

-

-12,793

-12,573

-8,079

-16,046

-7,696

14,459

2,450

-9,975

-9,272

-2,262

12,791

-

-

License
License and collaboration revenue

15,045

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration
License and collaboration revenue

1,321

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of license
Total operating expenses

3,047

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of collaboration
Total operating expenses

1,432

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-